Shenzhen Hepalink Pharmaceutical Co Ltd - Asset Resilience Ratio

Latest as of March 2026: 10.10%

Shenzhen Hepalink Pharmaceutical Co Ltd (002399) has an Asset Resilience Ratio of 10.10% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 002399 working capital efficiency to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

CN¥1.72 Billion

≈ $251.41 Million USD Cash + Short-term Investments

Total Assets

CN¥17.01 Billion

≈ $2.49 Billion USD All company assets

Resilience Assessment

Moderate

Financial Resilience Level

Asset Resilience Ratio Trend (2010–2025)

This chart shows how Shenzhen Hepalink Pharmaceutical Co Ltd's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see total assets of Shenzhen Hepalink Pharmaceutical Co Ltd.

Liquid Assets Composition Over Time

This chart breaks down Shenzhen Hepalink Pharmaceutical Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read total liabilities of Shenzhen Hepalink Pharmaceutical Co Ltd for a breakdown of total debt and financial obligations.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	CN¥0.00	0%
Short-term Investments	CN¥1.72 Billion	10.1%
Total Liquid Assets	CN¥1.72 Billion	10.10%

Asset Resilience Insights

Moderate Liquidity: Shenzhen Hepalink Pharmaceutical Co Ltd has 10.10% of assets in liquid form.
While adequate for normal operations, this level may limit flexibility during economic stress.
The company has significant short-term investments, indicating active treasury management.

Shenzhen Hepalink Pharmaceutical Co Ltd Industry Peers by Asset Resilience Ratio

Compare Shenzhen Hepalink Pharmaceutical Co Ltd's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Swedish Orphan Biovitrum AB (publ) ST:SOBI	Drug Manufacturers - Specialty & Generic	1.54%
Yunnan Baiyao Group Co Ltd SHE:000538	Drug Manufacturers - Specialty & Generic	8.38%
Guangdong Zhongsheng Pharmaceutical Co Ltd SHE:002317	Drug Manufacturers - Specialty & Generic	6.62%
Takeda Pharmaceutical Co Ltd ADR NYSE:TAK	Drug Manufacturers - Specialty & Generic	4.94%
Harbin Gloria Pharmaceuticals SHE:002437	Drug Manufacturers - Specialty & Generic	9.04%
Jiuzhitang Co Ltd SHE:000989	Drug Manufacturers - Specialty & Generic	7.86%
Renhe Pharmacy Co Ltd SHE:000650	Drug Manufacturers - Specialty & Generic	37.54%
Jiangsu Kanion Pharmaceutical Co Ltd SHG:600557	Drug Manufacturers - Specialty & Generic	0.29%

Annual Asset Resilience Ratio for Shenzhen Hepalink Pharmaceutical Co Ltd (2010–2025)

The table below shows the annual Asset Resilience Ratio data for Shenzhen Hepalink Pharmaceutical Co Ltd.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-12-31	8.92%	CN¥1.48 Billion ≈ $217.16 Million	CN¥16.63 Billion ≈ $2.43 Billion	+3.92pp
2024-12-31	5.01%	CN¥868.42 Million ≈ $127.08 Million	CN¥17.34 Billion ≈ $2.54 Billion	+2.85pp
2023-12-31	2.16%	CN¥414.18 Million ≈ $60.61 Million	CN¥19.20 Billion ≈ $2.81 Billion	-4.14pp
2022-12-31	6.30%	CN¥1.31 Billion ≈ $191.93 Million	CN¥20.81 Billion ≈ $3.05 Billion	+1.17pp
2021-12-31	5.13%	CN¥981.16 Million ≈ $143.57 Million	CN¥19.11 Billion ≈ $2.80 Billion	+0.78pp
2020-12-31	4.35%	CN¥828.21 Million ≈ $121.19 Million	CN¥19.03 Billion ≈ $2.78 Billion	+3.61pp
2019-12-31	0.74%	CN¥112.64 Million ≈ $16.48 Million	CN¥15.24 Billion ≈ $2.23 Billion	+0.16pp
2018-12-31	0.58%	CN¥79.22 Million ≈ $11.59 Million	CN¥13.66 Billion ≈ $2.00 Billion	-1.61pp
2017-12-31	2.19%	CN¥288.39 Million ≈ $42.20 Million	CN¥13.19 Billion ≈ $1.93 Billion	+2.08pp
2016-12-31	0.10%	CN¥13.40 Million ≈ $1.96 Million	CN¥12.91 Billion ≈ $1.89 Billion	-8.43pp
2015-12-31	8.54%	CN¥1.04 Billion ≈ $152.02 Million	CN¥12.17 Billion ≈ $1.78 Billion	+8.53pp
2014-12-31	0.00%	CN¥391.00K ≈ $57.22K	CN¥9.93 Billion ≈ $1.45 Billion	0.00pp
2013-12-31	0.01%	CN¥629.42K ≈ $92.10K	CN¥8.27 Billion ≈ $1.21 Billion	+0.00pp
2012-12-31	0.01%	CN¥529.83K ≈ $77.53K	CN¥8.26 Billion ≈ $1.21 Billion	-0.01pp
2011-12-31	0.01%	CN¥1.04 Million ≈ $152.47K	CN¥7.97 Billion ≈ $1.17 Billion	+0.01pp
2010-12-31	0.00%	CN¥-6.88K ≈ $-1.01K	CN¥8.13 Billion ≈ $1.19 Billion	--

pp = percentage points

About Shenzhen Hepalink Pharmaceutical Co Ltd

SHE:002399 China Drug Manufacturers - Specialty & Generic

Market Cap

$1.71 Billion

CN¥11.66 Billion CNY

Market Cap Rank

#6792 Global

#1402 in China

Share Price

CN¥9.35

Change (1 day)

-1.37%

52-Week Range

CN¥8.65 - CN¥12.56

All Time High

CN¥28.69